Impact of Thoracic Radiotherapy on First-Line Treatment Outcomes in ES-SCLC Patients

被引：0

作者：

Xiaoli, M. ^{[1
]}

Yan, L. ^{[2
]}

机构：

[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[2] Lung Canc Ctr, Chengdu, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Thoracic Radiotherapy; first-line immunotherapy and chemotherapy; extensive-stage small cell lung cancer;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP.13D.08

引用

页码：S678 / S678

页数：1

共 50 条

[21] Consolidative and salvage thoracic radiotherapy (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) with first-line chemoimmunotherapy: a retrospective study from a single cancer center
Lan, Aihua
Dong, Huiling
Zheng, Zhiqin
Chu, Xiao
Zhu, Zhengfei
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2025, 55
[22] Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133)
Horn, Leora
Mansfield, Aaron Scott
Reck, Martin
Mok, Tony
Spira, Alexander I.
Tang, Xiongwen
Lam, Sivuonthanh
Kabbinavar, Fairooz F.
Lopez-Chavez, Ariel
Sandier, Alan
Liu, Stephen V.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] Radioactive Seed Implantation Combined with PD-L1 Antibody and Chemotherapy Gt in the First-Line Treatment of ES-SCLC: A Retrospective Study
Li, X.
Zhang, W.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S669 - S669
[24] Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Ganti, A. K.
Prince, T.
Back, S.
Chansakul, A.
Boccuti, A.
Rengarajan, B.
Chakrabarti, D.
Li, W.
Fan, L.
Cao, Y.
D'Agostino, R., Jr.
Fan, X.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S664 - S665
[25] Benmelstobart With Anlotinib Plus Chemotherapy as First-Line Therapy for ES-SCLC: A Randomized, Double-Blind, Phase 3 Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 6 - 7
[26] Outcomes of First-Line Anti-PD-L1 Blockades Combined with Brain Radiotherapy (BRT) for Extensive-Stage SmallCell Lung Cancer (ES-SCLC) with Brain Metastases (BM)
Tian, Y.
Ma, J.
Zhu, H.
Yu, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E360 - E360
[27] Adebrelimab Combined with Famitinib and Chemotherapy as First-Line Therapy for ES-SCLC: A Phase II, Single-Arm Exploratory Research
Zhao, Y.
Yu, Y.
Zhang, M.
Liu, M.
Wang, S.
Zhang, L.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S661 - S661
[28] Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
Cheng, Y.
Yang, R.
Chen, J.
Zhang, W.
Xie, C.
Hu, Q.
Zhou, N.
Huang, C.
Wei, S.
Sun, H.
Li, X.
Yu, Y.
Lai, J.
Yang, H.
Fang, H.
Chen, H.
Zhang, P.
Gu, K.
Wang, Q.
Shi, J.
Yi, T.
Xu, X.
Ye, X.
Wang, D.
Xie, C.
Liu, C.
Zheng, Y.
Lin, D.
Zhuang, W.
Lu, P.
Yu, G.
Li, J.
Gu, Y.
Li, B.
Wu, R.
Jiang, O.
Wang, Z.
Wu, G.
Lin, H.
Zhong, D.
Xu, Y.
Shu, Y.
Wu, D.
Chen, X.
Wang, J.
Wang, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S44 - S44
[29] Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis
Gomez-Randulfe, Igor
Diaz, Sofia Silva
Escriu, Carles
Mohammed, Saara
Shah, Riyaz
Fuentes, Javier David Benitez
Cox, Samantha
Monaca, Federico
Bria, Emilio
Garcia-Campelo, Maria Rosario
Crook, Benjamin
Talbot, Toby
Leporati, Rita
Balachandran, Kirsty
Newsom-Davis, Tom
Hughes, Sarah
Cove-Smith, Laura
Taylor, Paul
Blackhall, Fiona
Califano, Raffaele
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[30] Genomics and Immune Infiltration Biomarkers for Short-term and Long-Term ES-SCLC Survivors with First-Line Chemoimmunotherapy
Jiang, Y.
Zhan, P.
Lv, T.
Song, Y.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S361 - S361

← 1 2 3 4 5 →